AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37417229 — intervention group
Group type: COMPARATOR
Intervention: Balloon-expandable SAPIEN 3 (S3)
Number of subjects: 739
Study 37417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 1 pass
Number of subjects: 202
Study 37417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 2 passes
Number of subjects: 202
Study 37417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) after 3 to 7 passes
Number of subjects: 202
Study 37417239 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) with failed reperfusion
Number of subjects: 202
Study 37417239 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 202
Study 37417601 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified star-shaped incision on gingival sulcus before zirconia crown placement
Number of subjects: 24
Study 37417601 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified star-shaped incision
Number of subjects: 24
Study 37417619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzable leukocyte extract (DLE) administered orally at 2 mg per day for 5 days, followed by 4 mg per week for 5 weeks, and then 2 mg per week for 5 weeks.
Number of subjects: 30
Study 37417631 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation technique
Number of subjects: 0
Study 37417631 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial release technique (MRT)
Number of subjects: 0
Study 37417631 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) to egg white (EW)
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE (sIgE) to EW
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT) to egg
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT) to egg in children younger than 2 years
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: BAT
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: sIgE followed by BAT
Number of subjects: 150
Study 37417650 — intervention group
Group type: EXPERIMENTAL
Intervention: Using 100% sensitivity and 100% specificity cut-offs followed by OFC
Number of subjects: 150
Study 37417650 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC to baked egg (BE)
Number of subjects: 150
Study 37417650 — intervention group
Group type: COMPARATOR
Intervention: DBPCFC to lightly cooked egg (LCE)
Number of subjects: 150
Study 37417725 — intervention group
Group type: EXPERIMENTAL
Intervention: abaloparatide-sMTS
Number of subjects: 511
Study 37417725 — intervention group
Group type: COMPARATOR
Intervention: abaloparatide-SC
Number of subjects: 511
Study 37417781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab plus standard of care (SoC)
Number of subjects: 0
Study 37417781 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study 37417781 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 0
Study 37417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 5050
Study 37417824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5050
Study 37417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, angiotensin receptor-neprilysin inhibitors
Number of subjects: 5050
Study 37417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5050
Study 37417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists
Number of subjects: 5050
Study 37417824 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or angiotensin receptor-neprilysin inhibitors+beta-blocker+mineralocorticoid receptor antagonist)
Number of subjects: 5050
Study 37417948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy to MRSI metabolic abnormalities, tumor bed, and residual contrast enhancements, with concomitant Temozolomide for 6 months.
Number of subjects: 180
Study 37417948 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) of 60 Gy with concomitant Temozolomide for 6 months.
Number of subjects: 180
Study 37417948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) of 60 Gy with an additional simultaneous integrated boost totaling 72 Gy.
Number of subjects: 180
Study 37417948 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) of 60 Gy.
Number of subjects: 180
Study 37417948 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Number of subjects: 180
Study 37417948 — intervention group
Group type: COMPARATOR
Intervention: Standard dose (SD) for O(6)-methylguanine-DNA methyltransferase (MGMT) methylated patients.
Number of subjects: 180
Study 37417970 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal Platelet-Rich Plasma
Number of subjects: 0
Study 37417970 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Platelet-Rich Plasma Noncrosslinked Hyaluronic Acid Injections
Number of subjects: 0
Study 37418031 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib plus gemcitabine plus carboplatin (GCb)
Number of subjects: 102
Study 37418031 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GCb) alone
Number of subjects: 102
Study 37418059 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Analgesic Sufficiency Status (PASS) measured by pre-tetanus-induced ANI variation
Number of subjects: 0
Study 37418059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and increased effect-site concentrations of remifentanil (2, 4, 6 ng/ml)
Number of subjects: 0
Study 37418060 — intervention group
Group type: EXPERIMENTAL
Intervention: Paratracheal pressure
Number of subjects: 0
Study 37418060 — intervention group
Group type: COMPARATOR
Intervention: Standard mask ventilation
Number of subjects: 0
Study 37418263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment (1000 U/kg/dose on days 1, 2, 3, 4, and 7)
Number of subjects: 500
Study 37418263 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin treatment
Number of subjects: 500
Study 37418303 — intervention group
Group type: EXPERIMENTAL
Intervention: COMET-SSI (n=409)
Number of subjects: 828
Study 37418303 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (n=419)
Number of subjects: 828
Study 37418304 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention leveraging EHR-based data and team-based care
Number of subjects: 10
Study 37418304 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 10
Study 37418363 — intervention group
Group type: EXPERIMENTAL
Intervention: Go NAPSACC+ Staff Wellness
Number of subjects: 168
Study 37418363 — intervention group
Group type: COMPARATOR
Intervention: Go NAPSACC
Number of subjects: 168
Study 37418498 — intervention group
Group type: EXPERIMENTAL
Intervention: iCARE Nigeria HIV treatment support intervention (peer navigation and SMS text message medication reminders)
Number of subjects: 0
Study 37418498 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 0
Study 37418583 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of injectable-platelet-rich fibrin (i-PRF) and type-1 collagen particles applied to the defect in adjunct to periapical surgery (n=19)
Number of subjects: 38
Study 37418583 — intervention group
Group type: COMPARATOR
Intervention: No guided bone regeneration procedures (Control group, n=19)
Number of subjects: 38
Study 37418643 — intervention group
Group type: EXPERIMENTAL
Intervention: EYS C2139Y variant (6416G>A)
Number of subjects: 150
Study 37418643 — intervention group
Group type: EXPERIMENTAL
Intervention: EYS C2139Y-related RP
Number of subjects: 150
Study 37418643 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier prevalence
Number of subjects: 150
Study 37418643 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted molecular therapy
Number of subjects: 150
Study 37418685 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and lenalidomide (R2) combination therapy: 20 mg oral lenalidomide from days 2 to 22 and IV rituximab 375 mg/m2 on day 1 for a maximum of 6 cycles.
Number of subjects: 0
Study 37418685 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of lenalidomide at 10 mg/d from days 1 to 21 for every 28 days for a total of 12 cycles after achieving partial or complete response.
Number of subjects: 0
Study 37418844 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 kcal mixed meal tolerance test (MMT)
Number of subjects: 32
Study 37418844 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 kcal high-fat MMT
Number of subjects: 32
Study 37418844 — intervention group
Group type: COMPARATOR
Intervention: isocaloric high-carbohydrate MMT
Number of subjects: 32
Study 37418844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat MMT
Number of subjects: 32
Study 37419055 — intervention group
Group type: EXPERIMENTAL
Intervention: cNSLBP participants
Number of subjects: 30
Study 37419055 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic adults (AA)
Number of subjects: 30
Study 37419129 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 12 μg
Number of subjects: 179
Study 37419129 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 48 μg
Number of subjects: 179
Study 37419129 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted 90 μg
Number of subjects: 179
Study 37419129 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted 12 μg
Number of subjects: 179
Study 37419144 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) 590 mg added to background multidrug therapy for 12 months
Number of subjects: 33
Study 37419144 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) 590 mg
Number of subjects: 33
Study 37419144 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS) with clofazimine or clofazimine plus azithromycin
Number of subjects: 33
Study 37419144 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin liposome inhalation suspension (ALIS)
Number of subjects: 33
Study 37419394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2STAR trial (26 Gy to prostate)
Number of subjects: 60
Study 37419394 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SMART trial (26 Gy to prostate + up to 32 Gy boost to DIL)
Number of subjects: 60
Study 37419632 — intervention group
Group type: EXPERIMENTAL
Intervention: EMONO+Audiovisual
Number of subjects: 120
Study 37419632 — intervention group
Group type: COMPARATOR
Intervention: EMONO alone
Number of subjects: 120
Study 37419633 — intervention group
Group type: EXPERIMENTAL
Intervention: dyadic expressive arts-based intervention (EXAT)
Number of subjects: 154
Study 37419633 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual waitlist control group
Number of subjects: 154
Study 37419639 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal ultrafiltration (UF)
Number of subjects: 112
Study 37419639 — intervention group
Group type: COMPARATOR
Intervention: Restrictive ultrafiltration (UF)
Number of subjects: 112
Study 37419638 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration (MDA) combined with artemisinin-based combination therapy (ACT)
Number of subjects: 24
Study 37419638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 37419646 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP) group receiving conditioning with clove oil scent paired with active and placebo opioids for 5 days, in addition to standard multimodal analgesia including opioids.
Number of subjects: 0
Study 37419646 — intervention group
Group type: COMPARATOR
Intervention: Standard multimodal analgesia including opioids (control group).
Number of subjects: 0
Study 37419693 — intervention group
Group type: EXPERIMENTAL
Intervention: Neqstent coil-assisted flow diverter (NQS) with platinum coils
Number of subjects: 38
Study 37419693 — intervention group
Group type: EXPERIMENTAL
Intervention: NQS
Number of subjects: 38
Study 37419867 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum doublet therapy
Number of subjects: 697
Study 37419867 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 697
Study 37419867 — intervention group
Group type: COMPARATOR
Intervention: Single-agent immunotherapy
Number of subjects: 697
Study 37419969 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 763
Study 37419969 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital food (control)
Number of subjects: 763
Study 37419971 — intervention group
Group type: EXPERIMENTAL
Intervention: NWT-03 supplementation
Number of subjects: 76
Study 37419971 — intervention group
Group type: EXPERIMENTAL
Intervention: NWT-03 supplementation (acute intake after intervention)
Number of subjects: 76
Study 37419971 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 37420006 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β-neutralizing antibody canakinumab
Number of subjects: 25
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for dizziness
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived health
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls and treatment for dizziness
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing loss
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness and self-perception of health
Number of subjects: 10092
Study 37420013 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness treatment
Number of subjects: 10092
Study 37420180 — intervention group
Group type: EXPERIMENTAL
Intervention: Family centered care (FCC) intervention with additional elements rolled out in a stepwise 6-month approach including NICU environment changes, staff training, parental education, and psychosocial support for parents.
Number of subjects: 0
Study 37420227 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CBCT sialography
Number of subjects: 46
Study 37420227 — intervention group
Group type: EXPERIMENTAL
Intervention: MR sialography
Number of subjects: 46
Study 37420268 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital therapy (Playball)
Number of subjects: 22
Study 37420268 — intervention group
Group type: COMPARATOR
Intervention: Non-digital therapy
Number of subjects: 22
Study 37420274 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06804103 3.0 mg/kg Q3W
Number of subjects: 93
Study 37420274 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06804103 4.0 mg/kg Q3W
Number of subjects: 93
Study 37420274 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06804103 (all doses)
Number of subjects: 93
Study 37420284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including A&F report, educational meetings, and facilitation visits
Number of subjects: 30
Study 37420284 — intervention group
Group type: COMPARATOR
Intervention: Simple Audit & Feedback (A&F)
Number of subjects: 30
Study 37420284 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 30
Study 37421271 — intervention group
Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12 at admission and 1, 6, and 12 months after discharge
Number of subjects: 2328
Study 37421271 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age, decompensated chronic HF, HF with mildly reduced ejection fraction, HF with preserved ejection fraction, depression symptoms, cognitive impairment, and each additional HF rehospitalization within 1 year of discharge
Number of subjects: 2328
Study 37421269 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcardiotomy ECMO
Number of subjects: 2058
Study 37421276 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third anterior-posterior diameter (APD) measurement in infants
Number of subjects: 182
Study 37421276 — intervention group
Group type: EXPERIMENTAL
Intervention: One-third anterior-posterior diameter (APD) measurement in children
Number of subjects: 182
Study 37421278 — intervention group
Group type: EXPERIMENTAL
Intervention: Tmax mismatch ratio >10 s/>6 s
Number of subjects: 213
Study 37421291 — intervention group
Group type: EXPERIMENTAL
Intervention: TEER with MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614
Study 37421291 — intervention group
Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study 37421320 — intervention group
Group type: EXPERIMENTAL
Intervention: In-laboratory titration polysomnography (tPSG)
Number of subjects: 60
Study 37421320 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy home sleep study (eHST)
Number of subjects: 60
Study 37421604 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab (C5 inhibitor), loading doses (one intravenous, four subcutaneous) and subsequent every-4-weeks subcutaneous maintenance doses per weight-based tiered-dosing schedule.
Number of subjects: 51
Study 37421604 — intervention group
Group type: EXPERIMENTAL
Intervention: Crovalimab (C5 inhibitor)
Number of subjects: 51
Study 37421844 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (3 days/week for 15 weeks)
Number of subjects: 65
Study 37421844 — intervention group
Group type: COMPARATOR
Intervention: Control (unchanged physical activity)
Number of subjects: 65
Study 37421995 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Language Recommendation (PLR)
Number of subjects: 295
Study 37421995 — intervention group
Group type: COMPARATOR
Intervention: Standard Language Version (SLV)
Number of subjects: 295
Study 37422010 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced, prolonged and intensified ECG-monitoring with continuous rhythm monitoring using an implantable cardiac monitor (ICM) for high-risk patients and repeated 7-day Holter ECGs for others.
Number of subjects: 5200
Study 37422010 — intervention group
Group type: COMPARATOR
Intervention: Standard of care monitoring (control arm) with rhythm monitoring at the discretion of participating centers, allowed for up to 7 days.
Number of subjects: 5200
Study 37422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilematovir 500 mg
Number of subjects: 72
Study 37422079 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilematovir 80 mg
Number of subjects: 72
Study 37422079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 37422192 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete HRM-BR
Number of subjects: 207
Study 37422192 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial/absent HRM-BR
Number of subjects: 207
Study 37422199 — intervention group
Group type: EXPERIMENTAL
Intervention: Total aPS/PT
Number of subjects: 83
Study 37422199 — intervention group
Group type: EXPERIMENTAL
Intervention: LAC potency
Number of subjects: 83
Study 37422199 — intervention group
Group type: EXPERIMENTAL
Intervention: aPC-R
Number of subjects: 83
Study 37422241 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 348
Study 37422241 — intervention group
Group type: COMPARATOR
Intervention: 3-L polyethylene glycol (PEG)
Number of subjects: 348
Study 37422250 — intervention group
Group type: EXPERIMENTAL
Intervention: Separated instrument removal (RSI) using a modified spinal needle technique
Number of subjects: 158
Study 37422250 — intervention group
Group type: EXPERIMENTAL
Intervention: RSI technique
Number of subjects: 158
Study 37422518 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01E (30 µg)
Number of subjects: 450
Study 37422518 — intervention group
Group type: COMPARATOR
Intervention: SCTV01C (20 µg)
Number of subjects: 450
Study 37422518 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (20 µg)
Number of subjects: 450
Study 37422659 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention targeting the mechanism (6 sessions over 8 weeks)
Number of subjects: 60
Study 37422659 — intervention group
Group type: COMPARATOR
Intervention: Assessment of the causes of incapacity (control condition, 6 sessions over 8 weeks)
Number of subjects: 60
Study 37422666 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous unfractionated heparin (UFH) therapy
Number of subjects: 456
Study 37422666 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous low-molecular-weight heparin (LMWH) injection
Number of subjects: 456
Study 37422688 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m², venetoclax, and pevonedistat
Number of subjects: 40
Study 37422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation (EG, n=25)
Number of subjects: 50
Study 37422751 — intervention group
Group type: COMPARATOR
Intervention: Sham-control (CG, n=25, 23 completed)
Number of subjects: 50
Study 37422751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 37422752 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM)
Number of subjects: 56
Study 37422752 — intervention group
Group type: COMPARATOR
Intervention: Sham application (control)
Number of subjects: 56
Study 37422772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 3 mg once daily
Number of subjects: 5
Study 37422772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 10 mg once daily
Number of subjects: 5
Study 37422772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 30 mg once daily
Number of subjects: 5
Study 37422772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 30 mg twice daily
Number of subjects: 5
Study 37422772 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY1128688 60 mg twice daily
Number of subjects: 5